Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
|Original language||English (US)|
|Number of pages||7|
|Journal||Clinical, Cosmetic and Investigational Dermatology|
|State||Published - Sep 2 2014|
- Psoriatic arthritis
ASJC Scopus subject areas